Clinical and Cost Analysis: Making Your Treatment Decision
Why 1.7mg Wegovy vs Mounjaro Price Comparison Matters at This Stage
The 1.7mg Wegovy dose represents a critical juncture in your weight management journey, occurring at weeks 13-16 before transitioning to maintenance therapy. At this stage, comparing 1.7mg Wegovy vs Mounjaro becomes essential as you're planning long-term treatment sustainability and cost considerations. Unlike earlier doses where you're focused on tolerance and initial response, the 1.7mg stage allows for meaningful evaluation of each medication's value proposition. EverydayMeds recognises that patients at this dose level are experienced users who need transparent pricing and reliable supply chains.
The financial commitment at the 1.7mg stage and beyond represents the largest portion of your total treatment investment, making cost comparison between Wegovy and Mounjaro particularly relevant. Both medications require long-term commitment for sustained results, with clinical evidence showing weight regain when treatment stops. At £139.99 for 1.7mg Wegovy, EverydayMeds provides competitive pricing that allows for informed comparison with Mounjaro's different dosing structure. Your choice between these prescription-only medicines should consider both immediate costs and long-term affordability alongside clinical factors.
Transparent Wegovy vs Mounjaro Pricing: 1.7mg and Beyond
EverydayMeds offers 1.7mg Wegovy at £139.99, with new customers using code FIRST40 and returning customers using DOSE25 at checkout to access these prices. For patients comparing 1.7mg Wegovy vs Mounjaro, our Elevate Duo bundle provides both 1.7mg and 2.4mg Wegovy for £369.99, ensuring seamless progression to maintenance dosing. This pricing transparency extends across our entire range, from starter doses at £79.99 through to maintenance therapy. The Consistency 1.7mg bundle offers two 1.7mg pens for £309.99, ideal for patients who may need extended time at this dose level.
Mounjaro follows a different dosing schedule with 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg options, requiring separate price evaluation based on your prescribed dose. The key advantage of our 1.7mg Wegovy vs Mounjaro comparison service is access to both medications through a single GPhC-registered pharmacy (#9012878), ensuring consistent clinical oversight and supply reliability. All prices include prescriber consultation, clinical assessment, and next-day cold-chain delivery, providing complete treatment value rather than medication-only costs.
Clinical Evidence Comparing Wegovy and Mounjaro Mechanisms
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). Wegovy contains semaglutide, a GLP-1 receptor agonist that may help reduce appetite and increase feelings of fullness. The 1.7mg dose represents the penultimate step before reaching the 2.4mg maintenance dose used in these pivotal trials.
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist with a different mechanism of action that may offer additional metabolic benefits. Both medications are prescription-only medicines that must be used alongside a reduced-calorie diet and increased physical activity. When comparing 1.7mg Wegovy vs Mounjaro, your prescriber can help determine which mechanism aligns best with your individual clinical profile and treatment goals.
How 1.7mg Wegovy Works in Your Weight Management Journey
Wegovy's active ingredient, semaglutide, mimics the action of GLP-1, a natural hormone that signals fullness to your brain after eating. At the 1.7mg dose level, you're experiencing near-maximal appetite suppression effects while your body prepares for the full 2.4mg maintenance dose. The medication works by slowing gastric emptying, reducing food cravings, and promoting satiety after smaller meals. This mechanism becomes particularly evident at the 1.7mg stage, where many patients report significant changes in their relationship with food and eating patterns. The weekly injection schedule provides consistent medication levels, supporting sustained appetite control throughout each dosing interval.
Streamlined Ordering Process for Both Wegovy and Mounjaro
EverydayMeds' clinical assessment takes just 3 minutes to complete online, covering your medical history, current medications, and weight management goals. Our qualified prescribers review each application within 3 working days (or 24 hours with express service), ensuring appropriate medication selection between Wegovy and Mounjaro options. Once approved, your medication ships via next-day delivery in temperature-controlled packaging that maintains the cold-chain requirements for both treatments. The assessment covers your experience with the previous Wegovy doses and evaluates your readiness for 1.7mg or consideration of Mounjaro alternatives. All prescriptions are dispensed from our GPhC-registered pharmacy (#9012878) with comprehensive patient information and injection guidance included.
Storage and Practical Considerations: 1.7mg Wegovy vs Mounjaro
Wegovy offers a practical advantage with 6 weeks of room temperature storage (below 30°C) once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. Both medications require refrigeration at 2-8°C before first use and come in pre-filled injection pens with similar administration techniques. The 1.7mg Wegovy dose maintains the same FlexTouch pen technology used throughout the dose escalation schedule, ensuring familiarity and confidence with your injection routine. Dose escalation timing differs between medications, with Wegovy following a structured 4-week progression compared to Mounjaro's flexible titration schedule based on tolerance and response. This storage advantage makes Wegovy particularly suitable for patients with travel requirements or those who prefer flexibility in their medication management routine.
Cost Optimisation Strategies for Long-term 1.7mg Wegovy vs Mounjaro Treatment
At the 1.7mg stage, patients often benefit from bundle purchasing to secure supply continuity and potentially reduce per-pen costs. The Elevate Duo bundle combining 1.7mg and 2.4mg Wegovy for £369.99 provides a strategic transition to maintenance therapy whilst ensuring uninterrupted treatment. For patients requiring extended time at 1.7mg before progressing, the Consistency 1.7mg bundle offers reliable supply management. Returning customers can access the DOSE25 discount code to maintain competitive pricing across subsequent orders.
Mounjaro's different dosing structure requires separate cost analysis, particularly as some patients may need dose adjustments that don't follow the standard progression. Both medications represent significant long-term investments, making the choice between 1.7mg Wegovy vs Mounjaro partly dependent on your individual dose requirements and progression timeline. EverydayMeds' transparent pricing structure allows for accurate cost planning regardless of which medication your prescriber recommends for your specific clinical situation.
Making Your Final Decision: Expert Support for Wegovy vs Mounjaro Selection
Your choice between 1.7mg Wegovy and Mounjaro should balance clinical suitability, cost considerations, and practical factors like storage and administration preferences. EverydayMeds' clinical team can provide guidance on both options, ensuring you understand the differences in mechanisms, dosing schedules, and expected progression timelines. The 1.7mg Wegovy dose represents an ideal evaluation point, as you're experiencing significant appetite suppression whilst approaching the maintenance phase used in clinical trials. Both Wegovy and Mounjaro are available from EverydayMeds — your prescriber can help determine which is right for you based on your individual response pattern and treatment goals. Visit our 1.7mg Wegovy page to begin your clinical assessment, or explore Mounjaro options if your prescriber determines this dual-agonist approach better suits your metabolic profile.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
